Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Although ticagrelor is recommended as opposed to clopidogrel in antiplatelet strategy for patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI), evidence is limited in patients with cardiogenic shock (CS).
Objective: This study aims to evaluate the comparative efficacy and safety profile of ticagrelor and clopidogrel in patients with STEMI-CS undergoing pPCI.
Methods: Using data from a nationwide, multicenter registry, eligible patients were stratified into clopidogrel or ticagrelor based on the choice of P2Y inhibitors within 24 h of first medical contact. Multivariable-adjusted Cox regression analyses, along with Cox models adjusted for propensity score matching and inverse probability treatment weighting were conducted to compare outcomes between ticagrelor and clopidogrel. The efficacy and safety outcomes were in-hospital all-cause mortality and major bleeding.
Results: Among 729 STEMI-CS patients in our cohort, 403 received clopidogrel and 326 received ticagrelor. Multivariable-adjusted Cox regression analyses showed that ticagrelor was not associated with a significant difference in all-cause mortality (adjusted HR: 1.04; 95% CI: 0.69-1.56; p = 0.840) and major bleeding (adjusted HR: 1.30; 95% CI: 0.62-2.76; p = 0.489) compared to clopidogrel. Consistent results were found in the analyses adjusted by propensity score matching and inverse probability of treatment weighting.
Conclusions: Our findings suggest that the choice of either ticagrelor or clopidogrel was feasible as a P2Y inhibitor for dual anti-platelet strategy in STEMI-CS patients undergoing pPCI, as no significant difference between these two agents was observed in all-cause mortality and major bleeding during hospitalization.
Trial Registration: ClinicalTrials.gov, NCT02306616. Registered 29 November 2014.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12016187 | PMC |
| http://dx.doi.org/10.1186/s12959-025-00721-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Twice-A-Day CLOpidogrel vs Ticagrelor to Reduce Short-Term MACE after Primary PCI: The TADCLOT Trial.
J Am Coll Cardiol
August 2025
National Institute of Cardiovascular Diseases (NICVD), Rafiqui Shaheed Road, Karachi- 75510, Pakistan.
Background: The first month post-primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) is the highest risk period for major adverse cardiovascular events (MACE), including stent thrombosis. Ticagrelor and double dose clopidogrel are effective antiplatelet therapies, but no head-to-head comparison exists in this setting.
Objectives: We sought to evaluate the efficacy of ticagrelor over twice daily clopidogrel in reducing MACE events within the first one month post primary PCI.
Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial.
Eur Heart J
August 2025
Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea.
Background And Aims: Limited data exist on optimal antiplatelet strategies for high-risk patients undergoing complex percutaneous coronary intervention (PCI). This study aimed to investigate the efficacy and safety of tailored antiplatelet treatment with temporal modulation of the intensity of platelet inhibition in patients undergoing complex high-risk PCI.
Methods: We randomly assigned 2018 patients with high-risk anatomical or clinical characteristics undergoing complex PCI to a tailored antiplatelet strategy with early escalation (low-dose ticagrelor at 60 mg twice daily plus aspirin <6 months) and late de-escalation (clopidogrel monotherapy >6 months) or dual antiplatelet therapy (clopidogrel plus aspirin for 12 months).
Ticagrelor/Prasugrel or clopidogrel in acute coronary syndrome and advanced chronic kidney disease: Is more potency worth the risk?
Int J Cardiol
August 2025
Hangzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University, Zhejiang, China. Electronic address:
Safety of Ticagrelor Compared to Clopidogrel in the Contemporary Management Through Invasive or Non-Invasive Strategies of Elderly Patients Presenting with Acute Coronary Syndromes.
J Clin Med
August 2025
The Royal Wolverhampton NHS Trust, New Cross Hospital, Wolverhampton WV10 0QP, UK.
ESC recommends ticagrelor over clopidogrel for the treatment of acute coronary syndrome (ACS) but the lack of evidence for elderly patients (≥75) and concerns over bleeding has led to significant variability in its use within the UK. Our aim is, therefore, to compare the safety of ticagrelor compared to clopidogrel in real-world elderly patients admitted with ACS and managed either medically or through percutaneous intervention. Unselected elderly patients (≥75) admitted to Royal Berkshire Hospital with ACS (2013-2015) were identified and followed for 1 year.
View Article and Find Full Text PDFAssociations of new intracranial haemorrhage, ischaemic stroke and survival with dual antiplatelet therapy regimen or duration after endovascular treatment for ruptured cerebral aneurysm.
Stroke Vasc Neurol
August 2025
Department of Surgery, National Cheng Kung University Hospital, Tainan, Taiwan
Background: Dual antiplatelet therapy (DAPT) is often necessary following endovascular treatment for ruptured cerebral aneurysms; however, the optimal drug combination and treatment duration remain uncertain.
Method: Patients with subarachnoid haemorrhage secondary to ruptured cerebral aneurysms were identified from the TriNetX database. Subjects were categorised based on DAPT regimen (aspirin+clopidogrel vs aspirin+ticagrelor) and duration (≥1 month, ≥3 months, ≥6 months).